Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BN9X
|
||||
| Former ID |
DAP000696
|
||||
| Drug Name |
Tirofiban
|
||||
| Synonyms |
AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Fibrinolytic Agents
|
||||
| Company |
Medicure Pharma
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H36N2O5S
|
||||
| InChI |
InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
|
||||
| InChIKey |
COKMIXFXJJXBQG-NRFANRHFSA-N
|
||||
| CAS Number |
CAS 144494-65-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10166, 7885766, 7980802, 8187132, 14783655, 14857107, 43118263, 46504678, 50064433, 50139241, 50139531, 50391991, 57314193, 93166521, 96025291, 103239849, 103917841, 104322017, 117631451, 125312375, 126681866, 127342496, 127342497, 127342498, 127342499, 127342500, 127342501, 127342502, 127654660, 134337985, 135035597, 137003470, 142529026, 152034391, 160964118, 162009837, 162174250, 174527528, 175268199, 178103199, 179116923, 196370621, 210275582, 210281230, 223435210, 223659393, 226395812, 251916814, 251918053
|
||||
| ChEBI ID |
ChEBI:9605
|
||||
| SuperDrug ATC ID |
B01AC17
|
||||
| SuperDrug CAS ID |
cas=144494655
|
||||
| Target and Pathway | |||||
| Target(s) | Glycoprotein IIb/IIIa receptor | Target Info | Modulator | [556264] | |
| Reactome | Platelet degranulation | ||||
| Elastic fibre formation | |||||
| PECAM1 interactions | |||||
| Molecules associated with elastic fibres | |||||
| Integrin cell surface interactions | |||||
| Syndecan interactions | |||||
| ECM proteoglycans | |||||
| Integrin alphaIIb beta3 signaling | |||||
| GRB2:SOS provides linkage to MAPK signaling for Integrins | |||||
| p130Cas linkage to MAPK signaling for integrins | |||||
| VEGFA-VEGFR2 Pathway | |||||
| MAP2K and MAPK activation | |||||
| References | |||||
| Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| Ref 541706 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6586). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.